Abstract:Background: Aberrant chronic inflammation and excess accumulation of lipids play a pivotal role in the occurrence and progression of atherosclerosis. (-)-Epigallocatechin-3-gallate (EGCG), the major catechins in green tea, displayed anti-atherosclerotic properties in vivo and in vitro. However, the effects and underlying mechanism of EGCG on atherosclerosis remain unclear. Methods: Male apolipoprotein E-knockout (ApoE-/-) mice (7 weeks old) fed with high-fat diet (HFD) were treated with normal saline or EGCG (40 mg/kg/d, i.g.) for 18 weeks. Atherosclerotic plaque and liver lipid accumulation were measured by Oil Red staining. Plasma lipids and cytokines were detected using commercial kits. The expression of protein and mRNA was analyzed by western blot and quantitative real-time reverse transcription-polymerase chain reaction, respectively. Results: EGCG administration markedly attenuated atherosclerotic plaque formation in HFD-fed ApoE-/- mice, which were accompanied by increased plasma interleukin-10 (IL-10) level and decreased plasma IL-6 and tumor necrosis factor-α (TNF-α) levels. In addition, EGCG modulated high-fat-induced dyslipidemia, evidencing by decreased total cholesterol (TC) and low-density lipoprotein levels and increased high-density lipoprotein level. Meanwhile, EGCG treatment alleviated high-fat-mediated liver lipid accumulation and decreased liver TC and triglyceride. Mechanistically, EGCG significantly modulated high-fat-induced hepatic tetratricopeptide repeat domain protein 39B (TTC39B) expression and its related genes (Lxrβ, Abcg5, Abcg8, Abca1, Srebf1, Scd1, Scd2, Fas, Elovl5, Mylip) expression in liver from ApoE-/- mice. Notably, EGCG remarkably induced hepatic liver X receptor α (LXRα) and LXRβ expression and inhibited both precursor and mature sterol regulatory element binding transcription factor-1 (SREBP-1) expression. Conclusion: Taken together, our data for the first time suggested that TTC39B was involved in EGCG-mediated anti-atherosclerotic effects through modulation of LXR/SREBP-1 pathway.

The Inhibitory Effect of (−)-Epicatechin Gallate on the Proliferation and Migration of Vascular Smooth Muscle Cells Weakens and Stabilizes Atherosclerosis

(-)-Epicatechin gallate blocked cellular foam formation in atherosclerosis by modulating CD36 expression in vitro and in vivo

(-)- <i>Epicatechin Gallate</i> Interferes with Atherosclerotic Lesions by Inhibiting the Foaming of RAW264.7 Cells Induced by ox-LDL

(-)-Epicatechin gallate prevented atherosclerosis by reducing abnormal proliferation of VSMCs and oxidative stress of AML 12 cells

(-)-Epigallocatechin Gallate Inhibits Endothelin-1-induced C-reactive Protein Production in Vascular Smooth Muscle Cells.

Green Tea Polyphenol Epigallocatechin-3-gallate Increases Atherosclerotic Plaque Stability in Apolipoprotein E-deficient Mice Fed a High-Fat Diet

Epigallocatechin-3-gallate Ameliorates LPS-induced Inflammation by Inhibiting the Phosphorylation of Akt and ERK Signaling Molecules in Rat H9c2 Cells

(-)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B

Effect of Green Tea Catechins on Vascular Cell Proliferation and Reactive Oxygen Species

Advances in the Anti-Atherosclerotic Mechanisms of Epigallocatechin Gallate

Epigallocatechin-3-gallate inhibits H 2 O 2 -induced apoptosis in Mouse Vascular Smooth Muscle Cells via 67kD Laminin Receptor

EGCG Attenuates Atherosclerosis Through the Jagged-1/Notch Pathway.

Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 Expression Through the 67-Κda Laminin Receptor and the TLR4/MAPK/NF-κB Signalling Pathway in Lipopolysaccharide-Induced Macrophages

Epigallocatechin gallate protects against homocysteine-induced vascular smooth muscle cell proliferation

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer

Inhibition of the PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins

Epigallocatechin Gallate Preserves Endothelial Function by Reducing the Endogenous Nitric Oxide Synthase Inhibitor Level

Epicatechin Gallate Protects HBMVECs from Ischemia/Reperfusion Injury Through Ameliorating Apoptosis and Autophagy and Promoting Neovascularization.

Epigallocatechin-3-gallate inhibits interleukin-6- and angiotensin II-induced production of C-reactive protein in vascular smooth muscle cells

Epigallocatechin-3-gallate Attenuates Lipopolysaccharide-Induced Inflammation in Human Retinal Endothelial Cells

Effects and Mechanisms of Icariin on Atherosclerosis.